Recently, many multinational pharmaceutical companies have made frequent moves!

Recently, many multinational pharmaceutical companies, including Takeda Pharmaceuticals, Johnson & Johnson, and Fuji Irvine Biotechnology, have made frequent moves, mainly including merging product lines, building new business experience centers, and innovation cooperation centers
.
Takeda Pharma: Merging Product Lines Recently, Takeda Pharma China confirmed that its pantoprazole sodium enteric-coated tablets and vonora fumarate raw tablets will merge product lines to better respond to the market environment
.
Among them, Vonola fumarate tablet is a new drug in the oral preparation market for peptic ulcer, and it is also the first potassium ion-competitive acid blocker (P-CAB) to be marketed in China, and the indication is reflux esophagitis
.
The product was approved by the State Food and Drug Administration at the end of 2019 and officially launched in China in May 2020.
At present, the product has entered the 2020 National Medical Insurance Catalogue
.
Data shows that in the first half of 2021, the terminal sales of Vonola fumarate tablets in Chinese public medical institutions exceeded 30 million yuan, with huge growth potential
.
At present, it is facing the impact of generic drug companies such as Shandong New Era and Sichuan Haihui
.
Pantoprazole sodium enteric-coated tablets are suitable for the treatment of duodenal ulcer, gastric ulcer and moderate to severe reflux esophagitis
.
This product is a national medical insurance category B variety
.
At present, China has approved the marketing of pantoprazole sodium API, enteric-coated tablets, enteric-coated capsules, injections and other dosage forms
.
Among them, pantoprazole sodium enteric-coated tablets (40mg) and pantoprazole sodium for injection (40mg) have successfully entered the fourth batch of national procurement
.
Relevant data show that the sales amount of pantoprazole sodium enteric-coated tablets in China in 2020 is about 3.
33 billion
.
According to the industry, digestion is Takeda’s traditional strengths, and it has a complete R&D pipeline, including core disease areas such as inflammatory bowel disease, celiac disease and other intestinal diseases, and gastrointestinal motility disorders
.
This adjustment may be Takeda China's rearrangement in the field of heavy digestion
.
Johnson & Johnson: Allergan Experience Center Launched Recently, the Johnson & Johnson Allergan Experience Center was officially completed
.
The center is one of the important education and training bases for Johnson & Johnson's eye health business in the field of professional ophthalmology.

.
With the aggravation of aging and changes in people's living habits and the way they use their eyes, the number of patients with many ophthalmic diseases such as refractive errors, cataracts, and dry eye is increasing
.
Data shows that, regardless of overlapping incidences, the number of patients with the three major eye diseases, myopia, dry eye and cataract alone, has exceeded 1 billion.
However, the current domestic ophthalmology professional team is facing severe challenges
.
It is reported that the Johnson & Johnson Allergan Experience Center has three main areas: microscopic phacoemulsification training area, astigmatism marking training area, and dry eye diagnosis and treatment area.
It is equipped with professional ophthalmic equipment and many cutting-edge training equipment.
Young and middle-aged ophthalmologists provide professional-level training scenarios and courses including animal eye experiments, optical parameter measurement, diagnosis and treatment of dry eye, etc.
, to improve the cataract surgery ability of grassroots doctors
.
Fujifilm Irwin Bio: Opening of ICC Innovation Cooperation Center Recently, Fujifilm Irwin Biotechnology (Suzhou) Co.
, Ltd.
, a subsidiary of Fujifilm, announced the official opening of its ICC Innovation Cooperation Center in Suzhou High-tech Zone
.
According to reports, the center will provide a variety of culture medium development and optimization services to customers in the entire Greater China region in the future to meet the growing market demand in China
.
According to the data, Fuji Irwin Bio is committed to providing customers around the world with excellent cell culture media and customized media solutions, and supporting their large-scale commercial production
.
"Testing and Calibration of Dry Body Temperature Calibrators" is about to be broadcast, welcome to sign up Disclaimer: In any case, the information or opinions expressed in this article do not constitute investment advice to anyone
.